Secukinumab gets EC approval for treating hidradenitis suppurativa
Time : 2nd of June 2023 04:49:25 PM
,
Cosentyx® (secukinumab) became the only new biologic approved in the last decade for this condition. It provided rapid symptom relief by week 4, with increasing response rates for up to a year. The safety profile of the drug was already established across other indications. The drug is also used fot treating plaque psoriasis, spondylitis, spondyloarthritis, and arthritis.
NovartisTags
secukinumab, hidradenitis suppurativa, ECRecent Posts
Illicit drugs could be the reason behind 30% of sudden cardiac deaths
3rd of August 2023 02:58:31 PM
3rd of August 2023 02:58:31 PM
